NATCOPHARM:NSE Natco Pharma Limited

INR 952.05 -21.45 -2.20339
Icon

Natco Pharma Limited (NATCOPHARM:NSE) Stock Analysis and Price Targets

COMMON STOCK | Drug Manufacturers - Specialty & Generic | NSE
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

INR 952.05

-21.45 (-2.20)%

INR 183.76B

0.49M

INR 977.00(+2.62%)

N/A

Icon

NATCOPHARM:NSE

Natco Pharma Limited (INR)
COMMON STOCK | NSE
INR 952.05
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

INR 183.76B

N/A

INR 952.05

Natco Pharma Limited (NATCOPHARM:NSE) Stock Forecast

INR 977.00
(+2.62%)

Based on the Natco Pharma Limited stock forecast from 1 analysts, the average analyst target price for Natco Pharma Limited is INR 977.00 over the next 12 months. Natco Pharma Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Natco Pharma Limited is Slightly Bullish , which is based on 6 positive signals and 4 negative signals. At the last closing, Natco Pharma Limited’s stock price was INR 952.05. Natco Pharma Limited’s stock price has changed by -0.07% over the past week, -3.20% over the past month and +72.75% over the last year.

No recent analyst target price found for Natco Pharma Limited
No recent average analyst rating found for Natco Pharma Limited

Company Overview Natco Pharma Limited

NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovar...Read More

NATCO House, Hyderabad, India, 500034

3,946

March

INR

India

Adjusted Closing Price for Natco Pharma Limited (NATCOPHARM:NSE)

Loading...

Unadjusted Closing Price for Natco Pharma Limited (NATCOPHARM:NSE)

Loading...

Share Trading Volume for Natco Pharma Limited Shares

Loading...

Compare Performance of Natco Pharma Limited Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for NATCOPHARM:NSE

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Natco Pharma Limited (Sector: Drug Manufacturers - Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE
Sun Pharmaceutical Industries .. +16.40 (+1.02%) INR3,736.24B 41.91 27.03

ETFs Containing NATCOPHARM

Symbol Name NATCOPHARM's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Natco Pharma Limited (NATCOPHARM:NSE) Stock

Based on ratings from 1 analysts Natco Pharma Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 1 buy, sell and hold ratings.

NATCOPHARM:NSE stock's dividend yield is 0.49%. Our analysis grades NATCOPHARM:NSE stock's dividend yield at F. This means that NATCOPHARM:NSE stock's dividend yield is above 48% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange. Based on this NATCOPHARM:NSE may be a average dividend stock for its sector.

Based on targets from 1 analysts, the average taret price for NATCOPHARM:NSE is INR 977.00 over the next 12 months. The maximum analyst target price is INR 977 while the minimum anlayst target price is INR 977.

NATCOPHARM:NSE stock's Price/Earning ratio is 14.47. Our analysis grades NATCOPHARM:NSE stock's Price / Earning ratio at B+. This means that NATCOPHARM:NSE stock's Price/Earning ratio is above 11% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange. Based on this NATCOPHARM:NSE may be undervalued for its sector.

The last closing price of NATCOPHARM:NSE's stock was INR 952.05.

The most recent market capitalization for NATCOPHARM:NSE is INR 183.76B.

Based on targets from 1 analysts, the average taret price for NATCOPHARM:NSE is projected at INR 977.00 over the next 12 months. This means that NATCOPHARM:NSE's stock price may go up by +2.62% over the next 12 months.

We can't find any ETFs which contains Natco Pharma Limited's stock.

As per our most recent records Natco Pharma Limited has 3,946 Employees.

Natco Pharma Limited's registered address is NATCO House, Hyderabad, India, 500034. You can get more information about it from Natco Pharma Limited's website at https://www.natcopharma.co.in.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...